Perampanel 6 MG

ApprovedCompleted
0 views this week 0 watching Active
Interest: 43/100
43
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Healthy

Conditions

Healthy

Trial Timeline

Oct 1, 2018 → Nov 29, 2021

About Perampanel 6 MG

Perampanel 6 MG is a approved stage product being developed by Eisai for Healthy. The current trial status is completed. This product is registered under clinical trial identifier NCT03653741. Target conditions include Healthy.

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03653741ApprovedCompleted

Competing Products

20 competing products in Healthy

See all competitors
ProductCompanyStageHype Score
AZD0837AstraZenecaPhase 1
29
ValsartanNovartisPhase 1
29
CSL112 + PlaceboCSLPhase 1
29
UT-15CUnited TherapeuticsPhase 1
26
VNA-318 + PlaceboBiotrialPhase 1
19
Open-label TRV734 125 mg + TRV734 blinded + Oxycodone IR 10 mg + PlaceboTrevenaPhase 1
19
TRV130 + Moxifloxacin + PlaceboTrevenaPhase 1
19
Radiolabeled TRV130TrevenaPhase 1
19
TRV130A + Dextrose in WaterTrevenaPhase 1
19
TRV734TrevenaPhase 1
19
ALT02 + EU-licensed Herceptin + US-licensed HerceptinAlteogenPhase 1
29
ENZ215 + EU Sourced Prolia + US Sourced ProliaAlkem LaboratoriesPhase 1
29
KPL-404Kiniksa PharmaceuticalsPhase 1
23
MORF-057 + Placebo for MORF-057Eli LillyPhase 1
29
Propranolol + PseudoephedrineEli LillyPre-clinical
26
LY2157299Eli LillyPhase 1
29
Lasmiditan + PlaceboEli LillyPhase 1
29
LY3015014 + PlaceboEli LillyPhase 1
29
LOXO-783Eli LillyPhase 1
29
LY2541546 - IV + LY2541546 - SC + PlaceboEli LillyPhase 1
29